Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: The combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity

Clinical Biochemistry

Volumn 36, Issue 6, 2003, Pages 421-429

  Rashid, Shirya ^a   Watanabe, Takehiko ^a   Sakaue, Taro ^a   Lewis, Gary F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apolipoprotein A I; Atherosclerotic cardiovascular disease; Cholesteryl ester transfer protein; Hepatic lipase; High density lipoprotein (HDL); Hypertriglyceridemia; Insulin resistance syndrome; Metabolic syndrome; Type 2 diabetes

Indexed keywords

CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENZYME ACTIVITY; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 0042762945     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(03)00078-X     Document Type: Review

References (105)

1. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults findings from the third National Health and Nutrition Examination Survey . JAMA. 287:2002;356-359.
2. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. [Review] [71 refs] Diabetes. 37:1988;1595-1607.
3. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75:1995;473-486.
4. Lewis G.F., Steiner G. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus. [Review] [204 refs] Diabetes Metab Rev. 12:1996;37-56.
5. Lamarche B., Lewis G.F. Atherosclerosis prevention for the next decade risk assessment beyond low density lipoprotein cholesterol . [Review] [104 refs] Can J Cardiol. 14:1998;841-851.
6. Ginsberg H.N. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. [Review] [180 refs] Diabetes Care. 14:1991;839-855.
7. Reaven G. Metabolic syndrome pathophysiology and implications for management of cardiovascular disease . Circulation. 106:2002;286-288.
8. Lamarche B., Rashid S., Lewis G. HDL metabolism in hypertriglyceridemic states an overview . Clin Chim Acta. 286:1999;145-161.
9. Sacks F.M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease expert group recommendations . Am J Cardiol. 90:2002;139-143.
10. Despres J.P., Lemieux I., Dagenais G.R., et al. HDL-cholesterol as a marker of coronary heart disease risk the Quebec cardiovascular study . Atherosclerosis. 153:2000;263-272.
11. Luc G., Bard J.M., Ferrieres J., et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction . Arterioscler Thromb Vasc Biol. 22:2002;1155-1161.
12. Nofer J., Kehrel B., Fobker M., et al. HDL and arteriosclerosis beyond reverse cholesterol transport . Atherosclerosis. 161:2002;1-16.
13. von Eckardstein A., Nofer J.R., Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 21:2001;13-27.
14. Schaefer E.J. Clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency. Arterioscler. 4:1984;303-322.
15. Brewer H.B., Santamarina-Fojo S., Hoeg J.M. Disorders of lipoprotein metabolism. Degroot L.J. Endocrinology. volume 3:1995;2731-2753 W.B. Saunders, Philadelphia.
16. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 22:1999;336-345.
17. Ng D.S., Leiter L.A., Vezina C., et al. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 93:1994;223-229.
18. Sirtori C.R., Calabresi L., Franceschini G., et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant the Limone sul Garda study . Circulation. 103:2001;1949-1954.
19. Rashid S., Uffelman K., Lewis G.F. The mechanism of HDL lowering in hypertriglyceridemic, insulin resistant states. J Diabetes Complications. 16:2002;24-28.
20. Syvanne M., Taskinen M.R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 350:(Suppl 1):1997;SI20-SI23.
21. Adeli K., Taghibiglou C., Van Iderstine S.C., et al. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 11:2001;170-176.
22. Lewis G.F., Carpentier A., Adeli K., et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 23:2002;201-229.
23. Brunzell J.D., Hazzard W.R., Porte D. Jr, et al. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest. 52:1973;1578-1585.
24. Connelly P.W., Maguire G.F., Vezina C., et al. Kinetics of lipolysis of very low density lipoproteins by lipoprotein lipase. Importance of particle number and noncompetitive inhibition by particles with low triglyceride content. J Biol Chem. 269:1994;20554-20560.
25. Jansen H., Breedveld B., Schoonderwoerd K. Role of lipoprotein lipases in postprandial lipid metabolism. Atherosclerosis. 141:(Suppl 1):1998;S31-S34.
26. Haidari M., Leung N., Mahbub F., et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem. 277:2002;31646-31655.
27. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest. 106:2000;453-458.
28. Patsch J.R., Prasad S., Gotto A.M. Jr, et al. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest. 80:1987;341-347.
29. Ginsberg H.N. Diabetic dyslipidemia basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels . Diabetes. 45:1996;S27-30.
30. Nikkila E.A., Taskinen M.R., Sane T. Plasma high-density lipoprotein concentration and subfraction distribution in relation to triglyceride metabolism. [Review] Am Heart J. 113:1987;543-548.
31. Lewis G.F., O'Meara N.M., Soltys P.A., et al. Postprandial lipoprotein metabolism in normal and obese subjects comparison after the vitamin A fat-loading test . J Clin Endocrinol Metab. 71:1990;1041-1050.
32. Lewis G.F., O'Meara N.M., Soltys P.A., et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab. 72:1991;934-944.
33. Patsch J.R., Karlin J.B., Scott L.W., et al. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci U S A. 80:1983;1449-1453.
34. Tall A.R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. [Review] J Clin Invest. 86:1990;379-384.
35. Eisenberg S. Lipoprotein abnormalities in hypertriglyceridemia significance in atherosclerosis . Am Heart J. 113:1987;555-561.
36. Mann C.J., Yen F.T., Grant A.M., et al. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 88:1991;2059-2066.
37. Foger B., Ritsch A., Doblinger A., et al. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 16:1996;1430-1436.
38. Clay M.A., Newnham H.H., Forte T.M., et al. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim Biophys Acta. 1124:1992;52-58.
39. Pulawa L.K., Eckel R.H. Overexpression of muscle lipoprotein lipase and insulin sensitivity. Curr Opin Clin Nutr Metab Care. 5:2002;569-574.
40. Yost T.J., Eckel R.H. Regional similarities in the metabolic regulation of adipose tissue lipoprotein lipase. Metabolism. 41:1992;33-36.
41. Yost T.J., Froyd K.K., Jensen D.R., et al. Change in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus. Metabolism. 44:1995;786-790.
42. Merkel M., Eckel R.H., Goldberg I.J. Lipoprotein lipase genetics, lipid uptake, and regulation . J Lipid Res. 43:2002;1997-2006.
43. Brinton E.A., Eisenberg S., Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb. 14:1994;707-720.
44. Brinton E.A., Eisenberg S., Breslow J.L. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 87:1991;536-544.
45. Horowitz B.S., Goldberg I.J., Merab J., et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 91:1993;1743-1752.
46. Vajo Z., Terry J.G., Brinton E.A. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis. 160:2002;495-501.
47. Pont F., Duvillard L., Florentin E., et al. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int J Obes Relat Metab Disord. 26:2002;1151-1158.
48. Frenais R., Ouguerram K., Maugeais C., et al. High density lipoprotein apolipoprotein AI kinetics in NIDDM a stable isotope study . Diabetologia. 40:1997;578-583.
49. Le N.A., Ginsberg H.N. Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism. 37:1988;614-617.
50. De Oliveira e Silva E.R., Kong M., Han Z., et al. Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females. J Lipid Res. 40:1999;1211-1221.
51. Pietzsch J., Julius U., Nitzsche S., et al. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes. 47:1998;1928-1934.
52. Morton R.E., Zilversmit D.B. Inter-relationship of lipids transferred by the lipid transfer protein isolated from human lipoprotein-deficient plasma. J Biol Chem. 258:1983;11751-11757.
53. Guerin M., Le Goff W., Lassel T.S., et al. Proatherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes impact of the degree of triglyceridemia . Arterioscler Thromb Vasc Biol. 21:2001;282-288.
54. Castle C.K., Kuiper S.L., Blake W.L., et al. Remodeling of the HDL in NIDDM a fundamental role for cholesteryl ester transfer protein . Am J Physiol. 274:1998;E1091-E1098.
55. Lewis G.F., Rashid S., Uffelman K., et al. Mechanism of HDL lowering in insulin resistant states. Angel A., Dhalla N., Pierce G., Singal P. Diabetes and Cardiovascular Disease: Etiology, Treatment and Outcomes. 2001;273-277 Klewer Academic/Plenum, New York, NY.
56. Patsch J.R., Prasad S., Gotto A.M. Jr, et al. Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. J Clin Invest. 74:1984;2017-2023.
57. Liang H.Q., Rye K.A., Barter P.J. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J Lipid Res. 35:1994;1187-1199.
58. Lamarche B., Uffelman K.D., Carpentier A., et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 103:1999;1191-1199.
59. Sparks D.L., Davidson W.S., Lund-Katz S., et al. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-1 structure and particle stability. J Biol Chem. 270:1995;26910-26917.
60. Clay M.A., Newnham H.H., Barter P.J. Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler Thromb. 11:1991;415-422.
61. Rashid S., Uffelman K., Barrett P.H.R., et al. Triglyceride enrichment of HDL does not alter HDL selective cholesteryl ester clearance in rabbits. J Lipid Res. 42:2001;265-271.
62. Jin W., Marchadier D., Rader D.J. Lipases and HDL metabolism. Trends Endocrinol Metab. 13:2002;174-178.
63. Hopkins G.J., Barter P.J. Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins. J Lipid Res. 27:1986;1265-1277.
64. Jaye M., Lynch K.J., Krawiec J., et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 21:1999;424-428.
65. Newnham H.H., Barter P.J. Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase. Biochim Biophys Acta. 1125:1992;297-304.
66. Olivecrona G., Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol. 6:1995;291-305.
67. Bengtsson G., Olivecrona T. The hepatic heparin releasable lipase binds to high density lipoproteins. FEBS Lett. 119:1980;290-292.
68. Thuren T. Hepatic lipase and HDL metabolism. J Lipid Res. 11:2000;277-283.
69. Shirai K., Barnhart R.L., Jackson R.L. Hydrolysis of human plasma high density lipoprotein 2- phospholipids and triglycerides by hepatic lipase. Biochem Biophys Res Commun. 100:1981;591-599.
70. Connelly P.W. The role of hepatic lipase in lipoprotein metabolism. Clin Chim Acta. 286:1999;243-255.
71. Doolittle M.H., Wong H., Davis R.C., et al. Synthesis of hepatic lipase in liver and extrahepatic tissues. J Lipid Res. 28:1987;1326-1334.
72. Sanan D.A., Fan J., Bensadoun A., et al. Hepatic lipase is abundant on both hepatocyte and endothelial cell surfaces in the liver. J Lipid Res. 38:1997;1002-1013.
73. Ji Z.S., Dichek H.L., Miranda R.D., et al. Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem. 272:1997;31285-31292.
74. Perret B., Mabile L., Martinez L., et al. Hepatic lipase structure/function relationship, synthesis, and regulation . J Lipid Res. 43:2002;1163-1169.
75. Syvanne M., Ahola M., Lahdenpera S., et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res. 36:1995;573-582.
76. Laakso M., Sarlund H., Ehnholm C., et al. Relationship between postheparin plasma lipases and high-density lipoprotein cholesterol in different types of diabetes. Diabetologia. 30:1987;703-706.
77. Carr M.C., Hokanson J.E., Deeb S.S., et al. A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women. Arterioscler Thromb Vasc Biol. 19:1999;2701-2707.
78. Purnell J.Q., Kahn S.E., Albers J.J., et al. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab. 85:2000;977-982.
79. Despres J.P., Ferland M., Moorjani S., et al. Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arterioscler. 9:1989;485-492.
80. Nie L., Wang J., Clark L.T., et al. Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. J Lipid Res. 39:1998;1127-1130.
81. Botma G.J., Verhoeven A.J., Jansen H. Hepatic lipase promoter activity is reduced by the C-480T and G-216A substitutions present in the common LIPC gene variant, and is increased by Upstream Stimulatory Factor. Atherosclerosis. 154:2001;625-632.
82. Baynes C., Henderson A.D., Richmond W., et al. The response of hepatic lipase and serum lipoproteins to acute hyperinsulinaemia in type 2 diabetes. Eur J Clin Invest. 22:1992;341-346.
83. Knauer T.E., Woods J.A., Lamb R.G., et al. Hepatic triacylglycerol lipase activities after induction of diabetes and administration of insulin or glucagon. J Lipid Res. 23:1982;631-637.
84. Baynes C., Henderson A.D., Anyaoku V., et al. The role of insulin insensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes. Diabet Med. 8:1991;560-566.
85. Murtomaki S., Tahvanainen E., Antikainen M., et al. Hepatic lipase gene polymorphisms influence plasma HDL levels. Results from Finnish EARS participants. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol. 17:1997;1879-1884.
86. Guerra R., Wang J., Grundy S.M., et al. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A. 94:1997;4532-4537.
87. Hegele R.A., Harris S.B., Brunt J.H., et al. Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis. 146:1999;153-160.
88. Tahvanainen E., Syvanne M., Frick M.H., et al. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Invsestigators. J Clin Invest. 101:1998;956-960.
89. Rashid S., Barrett P.H., Uffelman K.D., et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol. 22:2002;483-487.
90. Rashid S., Trinh D.K., Uffelman K.D., et al. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native HDL apolipoprotein A-I. Circulation. 2003;. (In Press).
91. Fan J., Wang J., Bensadoun A., et al. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci U S A. 91:1994;8724-8728.
92. Dugi K.A., Amar M.J., Haudenschild C.C., et al. In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL. Arterioscler Thromb Vasc Biol. 20:2000;793-800.
93. Lambert G., Chase M.B., Dugi K., et al. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor BI. J Lipid Res. 40:1999;1294-1303.
94. Barrans A., Collet X., Barbaras R., et al. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem. 269:1994;11572-11577.
95. 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. J Biol Chem. 269:1994;11572-11577.
96. Guendouzi K., Collet X., Bertrand P., et al. Remnant high density lipoprotein2 particles produced by hepatic lipase display high-affinity binding and increased endocytosis into a human hepatoma cell line (HEPG2). Biochemistry. 37:1998;14974-14980.
97. Kambouris A.M., Roach P.D., Calvert G.D., et al. Retroendocytosis of high density lipoproteins by the human hepatoma cell line, HepG2. Arterioscler. 10:1990;582-590.
98. Silver D.L., Wang N., Tall A.R. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. J Clin Invest. 105:2000;151-159.
99. Rahim A.T., Miyazaki A., Morino Y., et al. Biochemical demonstration of endocytosis and subsequent resecretion of high-density lipoprotein by rat peritoneal macrophages. Biochim Biophys Acta. 1082:1991;195-203.
100. Rogler G., Herold G., Fahr C., et al. High-density lipoprotein 3 retroendocytosis a new lipoprotein pathway in the enterocyte (Caco-2) . Gastroenterology. 103:1992;469-480.
101. Vassiliou G., Benoist F., Lau P., et al. The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. J Biol Chem. 276:2001;48823-48830.
102. Karhapaa P., Malkki M., Laakso M. Isolated low HDL cholesterol. An insulin-resistant state. Diabetes. 43:1994;411-417.
103. Couillard C., Bergeron N., Bergeron J., et al. Metabolic heterogeneity underlying postprandial lipemia among men with low fasting high density lipoprotein cholesterol concentrations. J Clin Endocrinol Metab. 85:2000;4575-4582.
104. Lamarche B., Despres J.P., Pouliot M.C., et al. Metabolic heterogeneity associated with high plasma triglyceride or low HDL cholesterol levels in men. Arterioscler Thromb. 13:1993;33-40.
105. Jansen H., Verhoeven A.J., Sijbrands E.J. Hepatic lipase a pro- or anti-atherogenic protein? J Lipid Res. 43:2002;1352-1362.